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Abstract
Although angiogenesis is a hallmark feature of asthmatic inflammatory responses, therapeutic
anti-angiogenesis interventions have received little attention. Objective: Assess the effectiveness of
anti-angiogenic Sn2 lipase-labile prodrugs delivered via αvβ3-micellar nanotherapy to suppress
microvascular expansion, bronchial remodeling, and airway hyper-responsiveness in Brown Norway
rats exposed to serial house dust mite (HDM) inhalation challenges. Results: Anti-neovascular
effectiveness of αvβ3-mixed micelles incorporating docetaxel-prodrug (Dxtl-PD) or fumagillin-prodrug
(Fum-PD) were shown to robustly suppress neovascular expansion (p<0.01) in the upper
airways/bronchi of HDM rats using simultaneous 19F/1H MR neovascular imaging, which was
corroborated by adjunctive fluorescent microscopy. Micelles without a drug payload (αvβ3-No-Drug)
served as a carrier-only control. Morphometric measurements of HDM rat airway size (perimeter) and
vessel number at 21d revealed classic vascular expansion in control rats but less vascularity (p<0.001)
after the anti-angiogenic nanotherapies. CD31 RNA expression independently corroborated the
decrease in airway microvasculature. Methacholine (MCh) induced respiratory system resistance (Rrs)
was high in the HDM rats receiving αvβ3-No-Drug micelles while αvβ3-Dxtl-PD or αvβ3-Fum-PD micelles
markedly and equivalently attenuated airway hyper-responsiveness and improved airway compliance.
Total inflammatory BAL cells among HDM challenged rats did not differ with treatment, but αvβ3+
macrophages/monocytes were significantly reduced by both nanotherapies (p<0.001), most notably by
the αvβ3-Dxtl-PD micelles. Additionally, αvβ3-Dxtl-PD decreased BAL eosinophil and αvβ3+ CD45+
leukocytes relative to αvβ3-No-Drug micelles, whereas αvβ3-Fum-PD micelles did not. Conclusion:
These results demonstrate the potential of targeted anti-angiogenesis nanotherapy to ameliorate the
inflammatory hallmarks of asthma in a clinically relevant rodent model.
Key words: Asthma, Nanomedicine, Prodrug, Angiogenesis, Fluorine MRI, Respiratory function

Introduction
Asthmatic
symptoms
like
bronchial
hyper-responsiveness and overall reduced lung
function reflect the underlying structural changes to
the airway wall due to chronic inflammation.[1]
Among the notable structural remodeling features of

asthmatic airways is the long-recognized expansion of
the bronchial vascular bed. Earlier research showed
that alterations in bronchial blood flow or capacity in
asthmatic patients were quantitatively reflected as
changes in airway temperature. These changes in
http://www.thno.org
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airway temperature were unrelated to cardiac output
or pulmonary blood flow, suggesting that they were
associated with vascular expansion within the
bronchial circulation. [2-6] Systemic vascular
expansion in the lung is associated with macrophage
activation, elaborating pro-angiogenic chemokines
that stimulate neovascular expansion. [7, 8]
Anti-inflammatory
systemic
or
inhaled
corticosteroids are critical therapeutic drugs used in
the acute and chronic management of asthma
patients, which at higher doses elicit pleiotropic
pharmacologic vascular remodeling effects including
local vasoconstriction and inhibition of the production
of pro-angiogenic cytokines and chemokines. [9-12]
Neovastat, an anti-inflammatory marine cartilage
derivative,
suppressed
airway
inflammation
associated with reductions in vascular endothelial
growth factor (VEGF) and hypoxia-inducible
factor–2α (HIF-2α) expression in murine lung tissue in
ovalbumin-sensitized mice. [13] Despite the close
interrelationship of airway inflammation and
increased
microvascularity,
anti-angiogenesis
treatment, such as anti-VEGF therapy, has not been
considered, perhaps because such blockades can be
circumvented by alternative pro-angiogenic factors
and endothelial signaling pathways.
Fumagillin is a highly potent anti-angiogenic
mycotoxin that inhibits methionine aminopeptidase-2
in proliferating endothelial cells leading to
apoptosis.[14, 15] In its stabilized water soluble form,
designated TNP-470, it had anecdotal benefit in
cancer patients but at the systemic doses required
patients experienced mild to moderate neurocognitive
side-effects. [16-21] Native fumagillin incorporated
into
the
lipid
encapsulated
αvβ3-targeted
nanoparticles markedly lowered the effective dose in
preclinical cancer [22] and rheumatoid arthritis [23]
models, which was further reduced when included as
an Sn2 lipase labile phospholipid prodrug. [24, 25]
Paclitaxel, which interacts with tubulin also has
anti-angiogenic benefit. [26] However, the off-target
adverse profile of taxanes precludes their general
systemic use as an anti-angiogenic therapeutic for
asthma. Unlike native fumagillin, hydrophobic
taxanes were not effectively retained in lipid
encapsulated αvβ3-targeted nanoparticles during
circulation except when modified into an Sn2 lipase
labile prodrug. [27] Importantly, at an effective
anti-angiogenic drug level of taxane administered as
αvβ3-targeted Sn2 docetaxel prodrug nanoparticles in
the Vx2 rabbit cancer model, Abraxane dosed iv was
ineffective. [27]
In the present study, lipase labile phospholipid
prodrug forms of fumagillin (Fum-PD) or docetaxel
(Dxtl-PD) were incorporated into lipid-based micelles
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for targeted drug delivery in the context of asthma to
determine if anti-angiogenesis nanotherapy could
offer a new therapeutic approach to this serious
disease. [25, 27-29] In general, lipase labile prodrugs
inactivate chemotherapeutic compounds and prevent
premature drug-loss from the nanoparticle during
circulation. Sensitive functional groups of drugs are
sequestered within the hydrophobic acyl membrane
compartment and protected from the surrounding
water milieu. [30] Lipid prodrugs are delivered by a
mechanism termed “contact-facilitated drug delivery”
(CFDD). [31] For CFDD the targeted cell surface
receptor, e.g., αvβ3, is used as a “mooring” that allows
the lipid nanoparticle surface to form an irreversible
hemifusion complex with the target cell membrane.
[32, 33] The prodrugs transfer spontaneously into the
target cell outer and then inner membranes. The
continuity of the inner cell membrane with
intracellular membranes, except mitochondria,
distributes the prodrugs throughout the cellular
compartments. Within the cell a myriad of
intracellular lipases can cleave the Sn2 ester of the
lipid backbone, liberating and reactivating the
compound within the cytosol. Direct targeting of
proliferating neoendothelial cells with αvβ3-targeted
Fum-PD or Dxtl-PD nanoparticles induces apoptosis.
[24]
In this proof of concept study, the impact of
anti-neovascular therapy was evaluated as a
therapeutic regimen for asthma in a clinically relevant
animal model. The temporal and spatial distribution
of angiogenesis, vascularity, and airway reactivity in a
Brown Norway rat model following serial allergen
challenges with house dust mite (HDM) was recently
characterized by Wagner et al. [34] Utilizing this
model, the overarching objectives of this
proof-of-concept study were: 1) to confirm the
anti-angiogenic efficacy in asthma of αvβ3-targeted
Fum-PD or Dxtl-PD micelles using MR simultaneous
dual 19F/1H neovascular molecular imaging (3T); 2) to
assess the impact of anti-angiogenesis therapy on
airway hyper-reactivity and compliance response to
methacholine challenge; 3) to delineate the impact of
anti-angiogenesis treatment on airway vascular
morphology and structural remodeling; and 4) to
characterize the treatment effects on bronchial
alveolar lavage cell numbers and type.

Methods
Preparation of Sn2 lipase labile fumagillin
prodrug
A modified synthesis of the Sn2 prodrug was
developed and accomplished in two steps [29]: 1)
saponifying fumagillin dicyclohexylamine salt to
http://www.thno.org
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fumagillol, and 2) esterifying the product with
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine
(PAzPC).[29] (Figure 1A) Briefly, fumagillin
dicyclohexylamine salt (NCI) in 0.1N NaOH was
stirred at ambient temperature (4h). The reaction
mixture was extracted with ethyl ether (3X) and dried
with anhydrous Na2SO4. After filtering the Na2SO4 the
ether was evaporated to a yellow oil (yield ~60%). The
final structure of fumagillol was confirmed by MS.
A solution of 1-hexadecyl-2-azelaoyl-snglycero-3-phosphocholine (Paz-PC, Avanti Polar
Lipids) 1mM, 4-dimethylaminopyridine (DMAP)(5X)
and N,N'-dicyclohexyl-carbodiimide (DCC) (5X) was
added to 1mM fumagillol in minimal dry chloroform.
The reaction mixture was stirred overnight at ambient
temperature then passed over a short pad of silica gel
using EtOAc/n-hexane (1:1). The filtered solvent was
removed in vacuo, and the oil residue was purified by
using
column
chromatography
on
SiO2
EtOAc/n-hexane for elution to yield the fumagillol
prodrug (Fum-PD) compound as a pale yellowish
solid (yield: 54%). Mass spectroscopy (MS) confirmed
the final synthetic structure: m/z [C49H88NO13P,
calculated mass= 929.60, observed= 930].

Preparation of Sn2 lipase labile docetaxel
prodrug
For the present research modified synthesis of
docetaxel prodrug was developed. Docetaxel (Sigma
Aldrich) dissolved in dimethylformamide (DMF) 0.02
mmole/ml was combined with Paz-PC in chloroform
(0.02 mmole/ml) then carbodiimide (DCC) /
dimethylaminopyridine (DMAP) on silica was added.
The mixture was incubated at room temperature
overnight then filtered. The DMF was dried in vacuo
to a solid. (Figure 1B) The compound was isolated
and
purified
by
preparative
thin
layer
chromatography (prep-TLC) (50% yield) and the
structure confirmed by NMR and ESI MS
spectroscopy (Dxtl-PD: m/z [C76H115N2O23P, calculated
mass=1454.76, observed M+H+=1456]).

ανβ3-integrin antagonist homing ligand
The ανβ3-integrin antagonist was a quinalone
nonpeptide developed by Bristol-Myers Squibb
Medical Imaging (US patent 6,511,648 and related
patents)
and
provided
coupled
to
phosphatidylethanolamine through a polyethylene
glycol2000 spacer (ανβ3-PEG-PE, Kereos, Inc., Figure
1C). The antagonist was initially characterized as the
111In-DOTA conjugate RP478 and cyan 5.5 homologue
TA145.[35] PFC nanoparticles present ~300
ligands/particle with an IC50 of 50 pM for the
Mn2+-activated αvβ3-integrin. [36]
The
homing
high
specificity
of
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ανβ3-nanoparticles (>150 nm nominal diameter) was
previously characterized using microscopic histology
of Matrigel™ plugs implanted into Rag1tm1Mom Tg
(Tie-2-lacZ)182-Sato and C57Bl/6 mice [37], using
photoacoustic molecular imaging of neovascular
sprouting in a Matrigel™ plug model in rats [38], and
in an ischemic left pulmonary artery ligation (LPAL)
model of bronchial angiogenesis induction in rodents.
[39] Robust reproducibility of serial targeting and MR
molecular imaging within individual rabbits bearing
Vx2 tumors over approximately one week was also
reported. [40]

Synthesis of αvβ3-integrin targeted therapeutic
micelles
Therapeutic mixed micelles were prepared by
microfluidization using 20% (v/v) polysorbate 80
(NOF America), 2.0% (w/v) of a surfactant
co-mixture, and 1.7% (w/v) glycerin suspension in
carbonate buffer (pH 6.5). The surfactant co-mixture
of nanoparticles included: 97.8 mole% lecithin and 0.2
mole% of αvβ3-PEG-PE, and 2 mole% of Fum-PD or
Dxtl-PD. Drug concentrations of the therapeutic
micelles were equimolar (0.5mM). AlexaFluor™ or
rhodamine dyes for fluorescent microscopy were
coupled to PEG2000-PE lipid anchors (0.6 mole%) and
included in the surfactant co-mixture at the equimolar
expense of lecithin for fluorescent microscopy.
“No-Drug” nanoparticles excluded the 2 mole% of
Fum-PD or Dxtl-PD, which was replaced by lecithin.
Surfactant components were combined with the
polysorbate, buffer, and glycerin with pH adjusted to
6.5, and the mixtures were homogenized at 20,000 psi
for 4 minutes. The micelles were preserved under
inert gas in sterile sealed vials until use.

Synthesis of αvβ3-integrin targeted
perfluorocarbon nanoparticles for MR imaging
Phospholipids-encapsulated
perfluorocarbon
(PFC) nanoparticles (NP) for neovascular MR
molecular imaging were prepared as a microfluidized
suspension of 20% (v/v) perfluoroctylbromide
(PFOB, Exfluor Inc., Round Rock, TX), 2.0% (w/v) of a
surfactant co-mixture, and 1.7% (w/v) glycerin in pH
6.5 carbonate buffer as described above. The
surfactant co-mixture of nanoparticles included: ~
99.8 mole% lecithin and 0.2 mole% of αvβ3-PEG-PE.
Dyes, e.g. AlexaFluor™ or rhodamine, were coupled
to PEG2000-PE lipid anchors (0.6 mole%) and included
in the surfactant co-mixture at the equimolar expense
of lecithin for fluorescent microscopy. Typical particle
size determined by dynamic light scattering was 214 ±
20 nm with a polydispersity index of 0.15 ± 0.5 and
zeta potential, (ζ) of 23 ± 12 mV (Brookhaven
ZetaPlus, Brookhaven Instruments Corporation).
http://www.thno.org
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MR neovascular imaging response to
αvβ3-targeted Fum-PD and Dxtl-PD
nanotherapy
Male Brown Norway rats (BN, Charles River,
100 g) were administered house dust mite allergen
(HDM, Der p 1; 100 µg/100µl challenge, Greer
Laboratories) by intranasal inspiration, as previously
reported [34] on days 0, 5 and 7 followed by i.v.
αvβ3-No-Drug (n=6), αvβ3-Fum-PD (n=6) or
αvβ3-Dxtl-PD (n=6) on days 6 and 8 (35µl, 0.7
µmole/kg/dose to offset anticipated transbiliary
losses in rodents). [41] All animals were studied using
simultaneous dual 19F/1H MR neovascular imaging at
3T (Achieva 3T, Philips Healthcare, Andover, MA).
Animal protocols were approved by the Johns
Hopkins and Washington University Animal Care
and Use Committees.
On day 10, 2 days following the last
anti-angiogenesis nanotherapy, all HDM treatment
groups were administered αvβ3-PFOB NPs (35µl) via
tail vein catheter. Two hours later, the animals were
anesthetized with a non-fluorinated anesthetic
(ketamine/xylazine; 85/13 mg/kg) and imaged with
high-resolution simultaneous 19F/1H MRI using an
in-house custom dual-tuned solenoid transmit-receive
coil. Simultaneous 3D 19F/1H imaging was used
employing a novel steady state ultra-short echo time
(UTE) technique (TE/TR=0.1ms/1.96ms) with the
frequencies set to the resonance of 1H and the CF2
groups of the PFOB spectrum (offset 6328Hz from 19F;
representing 12 of 17 total 19F nuclei). [42-45] Using a
highly oversampled 3D radial readout scheme, a
series of 19F images were reconstructed, post facto, by
modifying the Nyquist weighting factor applied to
samples in k-space. A Nyquist value that provided the
optimal balance between the 19F signal-to-noise ratio
(SNR) and image resolution was selected and that
value was uniformly applied to each individual
animal[46]. 1H images were used at the original
resolution of 1.25x1.25x1.25 mm3. In this anesthetized
rat model, neither mathematical correction nor
respiratory gating were required to adjust for motion,
as the breathing motion was of the same order of
magnitude or less than the pixel resolution and any
related ghosting was averaged out over the 28 min
total scan time.
19F/1H

MR image analysis

MR data sets were imported into ImageJ (NIH)
for quantification of the 19F signal. The method for
measuring neovascularity was based upon the
integral of 19F signal intensity from αvβ3-PFOB NPs.
Lung regions of interest (ROIs) were defined from
anatomical matching of multi-slice 1H and 19F MR
datasets. These ROIs consistently included the heart
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in order to capture neovascularity located proximate
to the trachea. To determine the background noise
level, these same (size and shape) ROIs were
repositioned in the upper left area of the image,
devoid of any signal or potential respiratory-related
ghosting. For each 19F 2D image slice, the average
signal in this background ROI was calculated and
subtracted from the image to standardize. Small
experiment-to-experiment differences in absolute
image intensity due to variations in RF coil tuning or
animal position were referenced to a PFOB emulsion
standard placed with the field of view adjacent to the
animal. The normalized lung 19F signal was then
averaged across all lung ROI slices.

Microscopic imaging to corroborate MR
neovascular imaging
In a separate cohort (n=3/treatment) treated
identically to those animals used for 19F/1H MR
molecular imaging, animals were euthanized 2 hours
after injection of fluorescent αvβ3-PFOB NPs. Lungs
were inflated to a pressure of 12 cmH2O and infused
with warmed liquefied 1% agarose (42ºC). The upper
airway, major bronchi, and surrounding tissue were
resected and snap frozen in optimum cutting
temperature (OCT) compound. Tissues were
sectioned and fluorescent microscopic images (40x)
were obtained with an Olympus BX61 microscope.
Cell nuclei were stained blue with DAPI
(4',6-diamidino-2-phenylindole, dihydrochloride).

Pharmacokinetics of αvβ3-micelles in naive and
HDM challenged Brown Norway rats
Male BN rats (100 g; n=6) were administered
house dust mite allergen or PBS control by intranasal
instillation on days 0, 5 and 7. On day 8, αvβ3-micelles,
incorporating 2 mole% Gd-DTPA-bisoleate as a trace
marker in the surfactant commixture, were injected
via tail vein. Serial blood samples were drawn for
pharmacokinetic analysis 0, 5, 15, 30, 45, 60, 90 and
120 minutes post dose. Blood samples were analyzed
for gadolinium using ICP OES (Optima 8000,
Perkin-Elmer). The results were fit to a two
compartmental model (Gd3+ concentration = A e-αt + B
e-βt; GraphPad Prism 5.04).

Pathological response to anti-angiogenesis
nanotherapy in asthmatic Brown Norway rats
Using the sensitization protocol previously
discussed [34], separate cohorts of male BN rats (BN,
125-150 g) were given HDM allergen by intranasal
instillation twice/week for 3 wks. Following the
second HDM treatment each week, rats received
αvβ3-No-Drug, αvβ3-Fum-PD (1.0 µmole/kg/dose), or
αvβ3-Dxtl-PD (50µl, 1.0 µmole/kg/dose) by tail vein
http://www.thno.org
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injection (n=4 rats/group). Rats were studied one day
after the last intranasal challenge of HDM.
For these animals, lungs were inflated with Z-fix
(Anatech, Battle Creek, MI) to a pressure of 12 cmH2O
for 24 hr. The left lung was divided into three sections,
embedded in paraffin, and stained with hematoxylin
and eosin (H&E). Airways (all cut in cross-section;
max/min diameter ratio <1.5) were sized by basement
membrane perimeter (ImageJ, NIH) and the number
of blood vessels within the associated airway wall was
enumerated. Morphometry was determined in lung
sections from rats given αvβ3-No-Drug, αvβ3-Fum-PD,
or αvβ3-Dxtl-PD micelles (n=4 rats/group).

Airway smooth muscle responsiveness
following anti-angiogenesis nanotherapy
Following the same HDM and micelle dosing
regimen, male BN rats (n=6/treatment group)
αvβ3-Fum-PD,
or
received
αvβ3-No-Drug,
αvβ3-Dxtl-PD micelles 1 day after the second weekly
HDM instillation. After 3 weeks the rats were
anesthetized (ketamine /xylazine, 75/5 mg/kg),
intubated, and paralyzed (0.6 mg succinylcholine
chloride) and dynamic respiratory mechanics were
determined.
Animals
were
ventilated
(90
breaths/min; 8 ml/kg) and lung resistance and
compliance were measured (Scireq Flexivent).
Following the baseline measurements, cumulative
dose-response relationships to methacholine chloride
(MCh) aerosol (15 sec with an Aeroneb nebulizer) at
challenges of 0 (PBS vehicle), 0.1, 1.0, 3.0, and 5
mg/ml MCh were obtained.

RT-PCR of endothelial specific genes following
anti-angiogenesis nanotherapy
Based on previous findings and according to the
same procedures [34], CD31, an endothelial-related
gene, was evaluated in large airways of HDM
exposed rats given αvβ3-No-Drug (n=3), αvβ3-Fum-PD
(n=4), or αvβ3-Dxtl-PD (n=4) micelles. Total RNA was
isolated
from
homogenized
tracheal
tissue
(RNeasy;Qiagen) according to the manufacturer’s
protocol, cDNA was generated with QuantiTect
Reverse Transcription kit (Qiagen; Real-Time PCR
Detection System (Bio-Rad) settings and primers were
as previously reported. [34]

Bronchoalveolar lavage recovery and cytospin
preparation
Immediately after death, bronchoalveolar lavage
(BAL) was performed using three aliquots of warm
(37oC) saline (2 ml / aliquot, 0.9% NaCl) delivered to
the right lung and then gently aspirated (3-4 rats per
treatment group). One ml of the recovered volume
was separated and the cells were measured using a
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hemocytometer.
Total
cell
numbers
were
back-calculated. BAL cells (5 x104) were spun onto
glass slides by cyto-centrifugation, fixed and stained
with HEMA 3 STAT PACK kit (Fisher Scientific,
Kalamazoo, MI). The cytospin slides were
differentiated by standard cytological procedures.

FACS staining and flow cytometry of
bronchoalveolar lavage cells
BAL fluid was withdrawn as described above
and immediately centrifuged (1400 rpm, 5 min, 4°C).
The cell pellet was resuspended in PBS for FACS
staining. Dead cells were excluded using VIVID®
(Invitrogen). Cells were blocked with anti-rat CD32
(BD Pharmingen) and subjected to biotinylated
anti-αvβ3 (eBioscience). Subsequent surface staining
was performed using FITC anti-rat CD11c, Pacific
Blue anti-rat CD11b (Bio-Rad), APC anti-rat ED-9
(eBioscience), PE anti-rat MHC II (Santa Cruz) and
APC/Cy7 anti-rat CD45 (Biolegend). Cells were
acquired on a BD FACSAria (BD Biosciences) and
data were analyzed with FlowJo software (Tree Star,
Ashland, OR).

Statistics
Imaging data were statistically analyzed using
SAS (SAS Institute Inc.) using general linear models,
including ANOVA and ANOCOV employing Tukey’s
test for multiple comparisons for significant
F-statistics. Group replication was powered to detect a
50% or greater difference at an alpha level of 0.05 with
a beta power of 0.80. [47] Least-squares regression
was used to estimate the slopes of airway size
(perimeter, mm) versus vessel number within
treatment groups. Airway morphology data were
analyzed with two-way ANOVA controlling for the
within animal variability using Fisher’s LSD for mean
separation. Means with a probability of difference ≤
0.05 were accepted as significant. All nominal data are
presented as the mean ± the standard error of the
mean.

Results
Fum-PD and Dxtl-PD were synthesized by
modification of prior procedures as described in the
Methods section and illustrated schematically in
Figure 1A,B, respectively. The αvβ3-peptidomimetic
homing ligand utilized was provided as a gift (Kereos,
Inc, St. Louis). (Figure 1C) αvβ3-mixed micelles used
for drug delivery had nominal particle sizes of 16 ± 4
nm and polydispersities between 0.1 and 0.2 based on
dynamic light scattering (DLS) and an electrophoretic
potential (ζ) of -20 ± 6 mV, across batches. Figure 1D
presents a representative DLS distribution example
micelle
formulation.
for
an
αvβ3-Dxtl-PD
http://www.thno.org
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Pharmacokinetics of the αvβ3-micelles tagged
with a gadolinium-lipid tracer was studied in HDM
(n=3) and naïve rats (n=3) with no difference (p>0.05)
appreciated between the two groups. The results fit to
a two compartmental model (Gd3+ concentration = A
e-αt + B e-βt) were in very close agreement and were
pooled to provide alpha distribution half-life of 6.9
min and a beta elimination half-life of 154.6 min
estimates; the beta elimination rate unexpectedly
exceeded the sampling regimen. (Figure 1E)
The
early
induction
of
bronchial
neovascularization after ischemic left pulmonary
artery ligation and HDM sensitization was previously
validated and characterized using 19F/1H MR
molecular imaging and corroborating histopathology
and
functional
airway
studies.
[34,
39]
Anti-angiogenesis treatment of the asthmatic HDM
rats with αvβ3-Dxtl-PD or αvβ3-Fum-PD micelles
markedly and equally reduced (p<0.01) airway
neovascular MR signal when compared to asthmatic
animals receiving αvβ3-No-Drug micelles. (Figure
2A-C) The binding of the fluorescent αvβ3perfluorooctylbromide nanoparticles (αvβ3-PFOB-NP)
within the bronchus of an HDM rat following
αvβ3-Fum-PD micelles nanotherapy versus the dense
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accumulation of αvβ3-PFOB-NP along the large
airway following αvβ3-No-Drug micelles was readily
differentiated. (Figure 2 D, E) Qualitatively the
previously reported 19F signal intensities of
non-asthmatic control rats were similar to the control
19F imaging data in the present study. [34]
Anti-angiogenic MR molecular imaging results
were
corroborated
by
immunofluorescence
microscopy. The sparse binding of the red fluorescent
αvβ3-PFOB-NP within the bronchus of an HDM rat
following αvβ3-Fum-PD micelle nanotherapy versus
the dense accumulation of αvβ3-PFOB-NP along the
large airway following αvβ3-No-Drug micelles was
easily differentiated. (Figure 2 D, E) Red fluorescent
αvβ3-micelles accumulated within the HDM inflamed
bronchus and surrounding parenchyma, whereas
these particles administered to naïve rats (i.e., no
HDM treatment) had negligible binding within or
around the large pulmonary airways or vasculature.
(Figure 2F,G) Collectively, the results corroborate the
tomographic changes observed with 19F/1H MR
neovascular imaging with αvβ3-PFOB NP and showed
that integrin-targeted Fum-PD or Dxtl-PD micelles
effectively diminished angiogenesis in HDM rats.

Figure 1. A. Scheme 1 Synthesis of fumagillin (fumagillol) PAz-PC prodrug. B. Scheme 2 Synthesis of docetaxel prodrug. C. Structure
αvβ3-peptidomimetic-PEG2000-PE. D. Example of dynamic light scattering micelle particle size distribution (αvβ3-Dxtl-PD). E. Averaged pharmacokinetic profile of
αvβ3-micelles containing a Gd3+-lipid marker in the surfactant commixture. The two compartment model Gd3+ concentration (C) = A e-αt + B e-βt revealed an alpha
distribution half-life of 6.9 min and a beta elimination half-life of 154.6 min.
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Figure 2. A, B. 19F/1H MR molecular following anti-angiogenesis treatment in HDM rats with αvβ3-Dxtl-PD (right) revealed markedly reduced airway neovascular MR
signal when compared to the control asthmatic animals receiving αvβ3-No-Drug micelles (left). C. Histogram of 19F/1H MR tomographic molecular imaging results
showing equivalent reduction in neovascularity with anti-angiogenesis micelles (P<0.01). D. Sparse binding of the red fluorescent αvβ3-PFOB NPs within the bronchus
of an HDM rat following αvβ3-Fum-PD micelles nanotherapy. E. Heavy accumulation of red fluorescent αvβ3-PFOB NPs along the large airway following αvβ3-No-Drug
micelles. F. Red fluorescent αvβ3-micelles accumulated heavily within the HDM inflamed bronchus and surrounding parenchyma. G. Red fluorescent αvβ3-micelles
administered to naïve rats (i.e., no HDM treatment) had negligible nonspecific binding. Green autofluorescence was noted in the airway and vascular walls.

Progressive HDM inhalation over three weeks in
the Brown Norway rats was previously associated
with
increased
(p<0.05)
airway
vascularity
measurable with microscopy. [34] Gross airway and
vascular casts demonstrated increased vascularity in
HDM compared to control (PBS) rats after 3 wks of
sensitization. In that study, 3 wks of HDM
sensitization elicited an abundance of blood vessels
within the airway wall compared to a paucity of
bronchial vessels observed in the control bronchi.
Striking differences in the influx of inflammatory
cells, airway wall thickening, and smooth muscle
contraction were noted in the HDM rats relative to the
PBS controls. Further, the correlation slopes of airway
size (perimeter, mm) versus the number of vessels
normalized for airway area were different between
HDM and PBS rats (p=0.002) and reflected increased
numbers of vessels in HDM rats compared to PBS rats
over an equivalent size range of airways studied
(0.5-3mm).
These asthmatic changes were recapitulated at
three weeks in the present study. The anti-angiogenic
impact of serial αvβ3-Dxtl-PD or αvβ3-Fum-PD
micelles after HDM inhalation demonstrated by MRI
on day 10 was associated with profound attenuation
of airway vascularity at 21 days. Least-squares
regression slopes of airway size (perimeter, mm)
versus vessel number significantly differed among

treatment groups (p<0.001). Control HDM rats had
more vessels as revealed by the slope (4.9 ± 0.5) than
those receiving αvβ3-Dxtl-PD micelles (2.7 ± 0.3) or
αvβ3-Fum-PD micelles (3.8 ± 0.5), (p<0.001). Further,
the regression slope of αvβ3-Dxtl-PD micelle response
was lower than the αvβ3-Fum-PD micelle observation.
(p=0.0394). (Figure 3A) After normalizing vessel
number for airway size (i.e., diameter), both
(p<0.001;
n=41
airways)
and
αvβ3-Dxtl-PD
αvβ3-Fum-PD (p<0.001; n=45 airways) micelles
decreased vascularity to a similar extent relative to the
HDM rats receiving αvβ3-No-Drug micelles (n=55
airways). (Figure 3B)
The marked morphometric vascular changes
were corroborated by examining the RNA expression
of endothelial-specific genes in tracheal tissue. The
tracheal expression of CD31, a common biomarker of
nascent and mature endothelial cells, was determined
and compared to naïve tissue expression levels.
(Figure 3C) CD31 expression was markedly decreased
in large airway tissue after αvβ3-Dxtl-PD and
αvβ3-Fum-PD micelle treatment compared to the
HDM rats given αvβ3-No-Drug micelles (p<0.001).
Lung functional changes, a clinical hallmark of
asthma, were assessed in a separate cohort of HDM
rats that received αvβ3-Dxtl-PD, αvβ3-Fum-PD or
αvβ3-No-Drug micelles. Respiratory system resistance
(Rrs) was measured after increasing methacholine
http://www.thno.org
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(MCh) concentrations in each group. (Figure 4A)
Airway reactivity to MCh was markedly attenuated
among rats treated with αvβ3-Dxtl-PD or
αvβ3-Fum-PD micelles compared with HDM rats
receiving αvβ3-No-Drug particles (p<0.001), which
was equivalent to the resistance response reported for
naive rats previously. MCh airway responsiveness
did not differ between the αvβ3-Dxtl-PD or
αvβ3-Fum-PD nanotherapies. Respiratory system
compliance (Crs) in HDM rats following the 3mg
MCh challenge was greater after the anti-angiogenic
nanotherapies than in the αvβ3-No-Drug micelle
group (p<0.001) (Figure 4B). Airway smooth muscle
thickening correlates with response to MCh, but
additional morphological measurements were not
obtained to reconfirm this relationship in this study.
Bronchoalveolar (BAL) cell profiles were
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compared among HDM rats receiving αvβ3-No-Drug
micelles versus the αvβ3-Dxtl-PD or αvβ3-Fum-PD
micelle treatments. Total inflammatory cells
recovered were similar (p>0.05) between the groups
at 3 weeks. (Figure 5A) BAL cell differential profiles
among animals receiving αvβ3-Dxtl-PD micelles had a
lower (p<0.05) percentage of eosinophils compared to
HDM rats receiving αvβ3-Fum-PD or αvβ3-No-Drug
treatments. (Figure 5B) Further, αvβ3-Dxtl-PD
nanotherapy decreased αvβ3+ CD45+ leukocytes
(p<0.001) whereas αvβ3-Fum-PD and αvβ3-No-Drug
treatments had no effect. (Figure 5C) BAL flow
cytometry showed that both αvβ3-Fum-PD and
αvβ3-Dxtl-PD micelle treatments decreased (p<0.001)
αvβ3+ macrophage/monocyte numbers versus the
control micelles (Figure 5D).

Figure 3. A. Least-squares regression slopes of airway size (perimeter, mm) versus vessel number significantly differed among treatment groups (p<0.001). Control
HDM (●) rats receiving αvβ3-No-Drug had more blood vessels as revealed by the slope (4.9 ± 0.5) than those receiving αvβ3-Dxtl-PD micelles (2.7 ± 0.3, ◻) or
αvβ3-Fum-PD micelles (3.8 ± 0.5, ▲), (p<0.001). Further, the regression slope of αvβ3-Dxtl-PD micelle response was lower than the αvβ3-Fum-PD micelle
observation. (p=0.0394). B. After normalizing vessel number for airway size (i.e., diameter), both αvβ3-Dxtl-PD (p<0.0001) and αvβ3-Fum-PD (p<0.0003) micelles
decreased vascularity to a similar extent relative to the HDM rats receiving αvβ3-No-Drug micelles (n=4 rats/group; 2-way ANOVA and Fisher’s LSD). C. CD31
expression in the trachea of the three treatment groups compared to naïve tissue. Gene expression for CD31, a common endothelial cell marker, was markedly
decreased in large airway tissue (trachea) after αvβ3-Dxtl-PD and αvβ3-Fum-PD compared to αvβ3-No-Drug (p=0.0005).

Figure 4. Pulmonary functional changes in HDM rats receiving αvβ3-Dxtl-PD, αvβ3-Fum-PD or αvβ3-No-Drug micelles. A. Respiratory system resistance (Rrs) was
measured after increasing methacholine (MCh) concentrations showing markedly attenuated reactivity among rats treated with αvβ3-Dxtl-PD or αvβ3-Fum-PD
micelles. (*** p <0.001). B. Respiratory system compliance (Crs) in HDM rats following the 3mg MCh challenge showing greater compliance after the anti-angiogenic
nanotherapies.
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Figure 5. Bronchoalveolar (BAL) cell profiles. A. Total inflammatory cells recovered were similar between the groups at 3 weeks. B. BAL cell differential profiles
showed a lower (p<0.05) percentage of eosinophils (EOS) in HDM rats receiving αvβ3-Dxtl-PD micelle than αvβ3-Fum-PD or αvβ3-No-Drug treatments. C.
αvβ3-Dxtl-PD nanotherapy decreased αvβ3+ CD45+ leukocytes (p<0.001) whereas αvβ3-Fum-PD and αvβ3-No-Drug treatments had no effects. D. BAL flow cytometry
revealing that αvβ3-Fum-PD and αvβ3-Dxtl-PD micelle treatments decreased (p<0.001) αvβ3+ macrophage/monocyte numbers versus the control micelles
(αvβ3-Dxtl-PD > αvβ3-Fum-PD micelles).

Discussion
Structural remodeling of asthmatic airways has
long been associated with microvascular expansion of
the capillary bed. Although angiogenesis is a
hallmark feature of asthmatic inflammatory
responses, specific therapeutic anti-angiogenesis
interventions have not been considered. In the present
studies, anti-angiogenic prodrug therapeutics
delivered by a micelle therapy markedly suppressed
microvascularity, bronchial remodeling, and airway
hyper-responsiveness in HDM rats, suggesting for the
first time that direct anti-neovascular therapy can
contribute significantly to asthma management.
The bioactivity and effectiveness of Sn2 lipase
labile prodrugs of Dxtl and Fum delivered via
αvβ3-integrin targeted micelles in HDM rats was
definitively demonstrated noninvasively with 19F/1H
MR
neovascular
molecular
imaging
using
vascular-constrained αvβ3-PFOB nanoparticles and a
clinical 3T scanner. The spatial and temporal character
of neovascular expansion within the upper
airways/bronchi of the HDM rats given
αvβ3-No-Drug micelles recapitulated the 19F/1H MR
response previously reported at this field strength.
[34] However, the neovascular signal among rats
receiving αvβ3-Dxtl-PD micelles or αvβ3-Fum-PD was

greatly reduced, validating that the prodrugs retained
drug bioactivity and that αvβ3-micelles effectively
homed and bound to the neovasculature. These
19F/1H MR imaging results were corroborated by
immunofluorescent microscopic studies that also
delineated the differential targeting of fluorescent
αvβ3-PFOB nanoparticles (red) in HDM rats receiving
αvβ3-No-Drug and αvβ3-Dxtl-PD micelles. The
targeting of fluorescent αvβ3-micelles (red) into the
airway wall and local surrounding tissue in No-Drug
treated HDM rats but not in naïve animals is
congruent with the therapeutic effects measured.
Within this study, MR provided early
recognition of HDM induced airway inflammation as
reflected by neovascular expansion and provided a
quantitative read-out of anti-angiogenic treatment
response. In the broader context, this result and
previous reports of clinical 19F/1H MR molecular
imaging of the lung pose the prospect for more
detailed and quantitative image guided management
of asthma patients, particularly those with moderate
to severe disease. The workhorse imaging modality of
lung imaging is computed tomography (CT) and for
cancer is positron emission tomography/CT
(PET/CT). As healthcare costs associated with newer
biological precision medicine therapies soar for
patients with moderate and particularly severe
http://www.thno.org
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asthma, improved high-sensitivity noninvasive
nonionizing imaging to optimize and minimize the
use of these therapies will be welcome. [48-51]
Anticipating that repeat imaging studies will be used
in pediatric patients as well as adults, the
implementation of MRI techniques becomes highly
attractive and circumvents potential cumulative X-ray
risks.
Increased vascular density in the sub-epithelial
submucosa of the lungs of asthmatic patients as well
as other bronchial vasculature abnormalities is well
documented and associated with increased blood
flow and edematous airway thickening. [52] After 3
weeks of biweekly HDM challenges, morphometric
measurements of airway size (perimeter) and vessel
number revealed classic asthma-related vascular
expansion in the HDM rats receiving αvβ3-No-Drug
micelles. HDM rats given the anti-angiogenic
αvβ3-Dxtl-PD or αvβ3-Fum-PD micelle therapies had
dramatically less microvascularity, which was
confirmed by reduced CD31 RNA expression in these
animals compared to the αvβ3-No-Drug controls.
Increased vascularization was previously
correlated with airflow limitation and bronchial
hyper-responsiveness. [12, 53, 54] In the present
study, MCh induced respiratory system resistance
(Rrs) was high in the HDM rats receiving the
particles
but
markedly
and
αvβ3-No-Drug
equivalently attenuated among rats treated with
αvβ3-Dxtl-PD or αvβ3-Fum-PD micelles. Similarly,
respiratory system compliance (Crs) was increased
among HDM rats exposed to anti-angiogenic prodrug
nanotherapy compared with the No-Drug micelles.
Clearly,
the
relationship
between
airway
hyper-responsiveness and vascularity observed in
patients was observed in the HDM rat model, and by
extension the substantial improvements elicited by
αvβ3-Dxtl-PD or αvβ3-Fum-PD micelles in HDM rats
could reasonably translate into patients.
As expected, microscopic examination revealed
marked increases in inflammatory cells in HDM rat
airways and surrounding tissues that were not
appreciated in the lungs from control animals.
expression
heavily
Increased
αvβ3-integrin
co-localized with activated macrophages by
microscopy was also appreciated in BAL cells of
control HDM. However, αvβ3+ macrophages were
significantly reduced by both targeted nanotherapies
and significantly more so by the αvβ3-Dxtl-PD micelle
treatment. Anti-angiogenic therapy is typically
viewed from the perspective of neovasculature
pruning, but recent studies intensively examining the
effects of αvβ3-Fum-PD in inflammatory mouse
models have shown that direct anti-angiogenesis
therapy is also anti-inflammatory. [24]
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Fumagillin is well known to impact the
proliferation of neovascular endothelial cells, but this
mycotoxin has negligible effects on non-endothelial
cell types. [55] The overall outcome of a series of
detailed experiments to delineate the potential
mechanism for local inflammation suppression with
integrin-targeted
fumagillin
determined
that
endothelial nitric oxide (NO) derived and released
from the drug-targeted neoendothelial cells
modulated local macrophage inflammatory response
through AMP-activated protein kinase (AMPK).
NO-induced AMPK activation decreased the
mammalian target of rapamycin (mTOR) activity and
increased autophagic flux, as evidenced by p62
depletion and increased autolysosome formation.
Increased macrophage autophagy flux was associated
with degradation of IkappaB kinase (IKK),
suppression of the NF-ĸB-p65 signaling pathway, and
ultimately decreased inflammatory cytokine release.
[24] Thus, the anti-inflammatory impact of Fum-PD
was indirectly mediated through the endothelial NO
release with suppressive feedback on the local
macrophages.
αvβ3-micelles, similar in size to IgG antibodies,
penetrate into inflamed tissue readily. These micelles
can home and bind to extravascular targets [56],
including
macrophages
expressing
activated
Fum-PD
is
ineffective
when
αvβ3-integrin.
co-incubated with activated macrophages in culture,
but it is effective against vascular tubule formation in
vitro. [24, 57] Dxtl-PD can suppress macrophage
inflammatory cytokine release in vitro and in vivo, as
well as being anti-angiogenic [30] (Supporting
Information: S1). In the present study, αvβ3-Dxtl-PD
micelles, in addition to the anti-angiogenic
anti-inflammatory effects elicited by targeting
neoendothelial cells similar to αvβ3-Fum-PD micelles,
they likely bound phagocytic cells, possibly the M2
phenotype
macrophages
increased
in
antigen-induced asthma. Of note in breast cancer, M2
macrophages
uniquely
express
activated
αvβ3-integrin. [58]
αvβ3-Dxtl-PD micelles but not αvβ3-Fum-PD
micelles reduced BAL αvβ3+ CD45+ cells, probably as a
direct consequence of targeted taxane prodrug
delivery. This would be expected due to the
endothelial cellular specificity of fumagillin. BAL
eosinophils were generally elevated in the HDM rats,
but markedly reduced among animals receiving
αvβ3-Dxtl-PD micelles and not the αvβ3-Fum-PD
micelles. Since αvβ3-integrin expression by eosinophils
is uncommon, we hypothesize that the reduction of
eosinophils was related to αvβ3-Dxtl-PD impacting M2
macrophages
within
a
complex
Th1/Th2-macrophage-eosinophil cross-talk network.
http://www.thno.org
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[59-61] Further delineation of these complex
interrelationships is beyond the scope of this initial
study.
While the present report has shown for the first
time that targeted αvβ3-micelle nanotherapy can
ameliorate bronchial airway hyper-reactivity and
inflammatory characteristics of dust-mite induced
asthma in rats, specific mechanistic studies will be
required to deconvolve the disruption of the complex
roles of cellular inflammatory components and
chemokines involved in the pathologic remodeling
within the inflamed airways. Further, these data
demonstrate that HDM induced asthma can be
approached in a nontraditional therapeutic fashion,
additional research to optimize the pharmacology and
to elucidate the safety of this targeted therapeutic
micelle approach is warranted.

Conclusion
The results of this study clearly indicate that
direct anti-angiogenesis therapy with αvβ3-Dxtl-PD or
αvβ3-Fum-PD micelles can ameliorate asthma in the
house dust mite triggered Brown Norway rat model.
Airway
hyper-responsiveness
and
increased
microvascularity, classic hallmarks of asthma, were
significantly reduced with these treatments. Whereas
the dogma of efficacy surrounding anti-angiogenesis
therapy has been associated with the impact of
vascular pruning, in the current study αvβ3-Dxtl-PD
or αvβ3-Fum-PD micelles treatment of proliferating
neoendothelial
cells
led
to
secondary
anti-inflammatory benefits.
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Supporting Information S1.
http://www.thno.org/v07p0377s1.pdf
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αvβ3: alpha v beta 3 integrin
AMPK: adenosine monophosphate (AMP)-activated
protein kinase
ANOVA: analysis of variance
ANOCOV: analysis of covariance
APC: allophycocyanin
BAL: bronchoalveolar lavage
CD11b: cluster of differentiation 11 - antigen on
monocytes/macrophages and microglia
CD45: cluster of differentiation 11 - lymphocyte
common antigen
CD31: cluster of differentiation 31 - Platelet
endothelial cell adhesion molecule (PECAM)
CD32: cluster of differentiation 32 – Fc gamma
receptor on B-cells
CFDD: contact-facilitated drug delivery
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Crs: respiratory system compliance
CT: computed tomography
Cy7: cyanine7 - near infrared fluorescent dye
DAPI: 4',6-diamidino-2-phenylindole
DCC: carbodiimide
DMAP: dimethylaminopyridine
DMF: dimethylformamide
DOTA: tetraazacyclododecane-1,4,7,10-tetraacetic acid
DTPA: diethylenetriaminepentaacetic acid
Dxtl-PD: docetaxel-prodrug
ESI: electrospray ionization
FACS: fluorescence-activated cell sorting
FITC: fluorescein isothiocyanate
FOV: field of view
Fum-PD: fumagillin-prodrug
HDM: house dust mites
HIF-2α: hypoxia-inducible factor–2α
ICP-OES: inductively coupled plasma optical
emission spectrometry
IKK: IkappaB kinase
MCh: Methacholine
MR: magnetic resonance
MS: mass spectroscopy
mTOR: mammalian target of rapamycin
NCI: National Cancer Institute
NF-ĸB: nuclear factor kappa-light-chain-enhancer of
activated B cell
NFkB-p65: a subunit of NF-kappa-B transcription
complex
NMR: nuclear magnetic resonance
NO: nitric oxide
OCT: optimum cutting temperature
p62: nucleoporin p62 is a protein complex associated
with the nuclear envelope
PAzPC:
palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine
PBS: phosphate buffered saline
PE: phosphatidylethanolamine
PEG: polyethylene glycol
PET/CT: positron emission tomography/CT
PFOB: perfluorooctylbromine
psi: pounds per square inch
RF: radio frequency
RNA: ribonucleic acid
ROI: regions of interest
Rrs: respiratory system resistance
Sn2: stereospecific numbering-by convention the
hydroxyl group of the second carbon of glycerol
T: Tesla
TE: echo time
TR: repetition time
TNP-470: synthetic analog of fumagillin
UTE: ultra-short echo time
VEGF: vascular endothelial growth factor
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